Monoclonal antibody shows promising results for rare liver disease

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an anti-inflammatory and anti-fibrotic monoclonal…

Continue Reading

News Source: medicalxpress.com